These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 21793038)
1. Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease. Rockenstein E; Ubhi K; Pham E; Michael S; Doppler E; Novak P; Inglis C; Mante M; Adame A; Alvarez XA; Moessler H; Masliah E J Neurosci Res; 2011 Nov; 89(11):1812-21. PubMed ID: 21793038 [TBL] [Abstract][Full Text] [Related]
2. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867 [TBL] [Abstract][Full Text] [Related]
3. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. Rockenstein E; Adame A; Mante M; Moessler H; Windisch M; Masliah E J Neural Transm (Vienna); 2003 Nov; 110(11):1313-27. PubMed ID: 14628195 [TBL] [Abstract][Full Text] [Related]
4. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. Ubhi K; Rockenstein E; Vazquez-Roque R; Mante M; Inglis C; Patrick C; Adame A; Fahnestock M; Doppler E; Novak P; Moessler H; Masliah E J Neurosci Res; 2013 Feb; 91(2):167-77. PubMed ID: 23152192 [TBL] [Abstract][Full Text] [Related]
5. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease. Rockenstein E; Mante M; Adame A; Crews L; Moessler H; Masliah E Acta Neuropathol; 2007 Mar; 113(3):265-75. PubMed ID: 17131129 [TBL] [Abstract][Full Text] [Related]
6. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease. Rockenstein E; Mallory M; Mante M; Alford M; Windisch M; Moessler H; Masliah E J Neural Transm Suppl; 2002; (62):327-36. PubMed ID: 12456076 [TBL] [Abstract][Full Text] [Related]
7. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Ubhi K; Rockenstein E; Doppler E; Mante M; Adame A; Patrick C; Trejo M; Crews L; Paulino A; Moessler H; Masliah E Acta Neuropathol; 2009 Jun; 117(6):699-712. PubMed ID: 19252918 [TBL] [Abstract][Full Text] [Related]
8. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Masliah E; Armasolo F; Veinbergs I; Mallory M; Samuel W Pharmacol Biochem Behav; 1999 Feb; 62(2):239-45. PubMed ID: 9972690 [TBL] [Abstract][Full Text] [Related]
9. Xestospongin C, a Reversible IP3 Receptor Antagonist, Alleviates the Cognitive and Pathological Impairments in APP/PS1 Mice of Alzheimer's Disease. Wang ZJ; Zhao F; Wang CF; Zhang XM; Xiao Y; Zhou F; Wu MN; Zhang J; Qi JS; Yang W J Alzheimers Dis; 2019; 72(4):1217-1231. PubMed ID: 31683484 [TBL] [Abstract][Full Text] [Related]
10. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. McClean PL; Hölscher C Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293 [TBL] [Abstract][Full Text] [Related]
11. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. Rockenstein E; Adame A; Mante M; Larrea G; Crews L; Windisch M; Moessler H; Masliah E J Neural Transm (Vienna); 2005 Feb; 112(2):269-82. PubMed ID: 15657642 [TBL] [Abstract][Full Text] [Related]
18. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease. Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830 [TBL] [Abstract][Full Text] [Related]
19. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868 [TBL] [Abstract][Full Text] [Related]
20. Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome. Doppler E; Rockenstein E; Ubhi K; Inglis C; Mante M; Adame A; Crews L; Hitzl M; Moessler H; Masliah E Acta Neuropathol; 2008 Oct; 116(4):425-37. PubMed ID: 18600331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]